1333240-13-3 Usage
Molecular structure
2-(3-hydroxyphenyl)-5-[(4-methoxybenzyl)oxy]-3-methylpyrimidin-4(3H)-one consists of a pyrimidine ring with various functional groups attached to it.
Functional groups
The compound contains a hydroxyl group (-OH) attached to the phenyl ring, a methyl group (-CH3) attached to the pyrimidine ring, and a methoxybenzyl group (-OCH3-C6H4-CH2-) attached to the pyrimidine ring.
Aromatic rings
The compound has a phenyl ring (a six-carbon ring with alternating single and double bonds) and a pyrimidine ring (a six-membered nitrogen-containing ring with a double bond between two carbon atoms).
Potential pharmaceutical applications
Due to its unique structure and functional groups, 2-(3-hydroxyphenyl)-5-[(4-methoxybenzyl)oxy]-3-methylpyrimidin-4(3H)-one may have potential applications in the pharmaceutical industry.
Biological activities
The specific biological activities of 2-(3-hydroxyphenyl)-5-[(4-methoxybenzyl)oxy]-3-methylpyrimidin-4(3H)-one are not yet known and require further investigation to determine its potential therapeutic applications.
Synthesis and evaluation
Further research is needed to synthesize 2-(3-hydroxyphenyl)-5-[(4-methoxybenzyl)oxy]-3-methylpyrimidin-4(3H)-one and evaluate its biological activities and potential therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1333240-13-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,3,2,4 and 0 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1333240-13:
(9*1)+(8*3)+(7*3)+(6*3)+(5*2)+(4*4)+(3*0)+(2*1)+(1*3)=103
103 % 10 = 3
So 1333240-13-3 is a valid CAS Registry Number.
1333240-13-3Relevant academic research and scientific papers
INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS
-
, (2011/10/03)
The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.
